EBT-101 is under clinical development by Excision BioTherapeutics and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EBT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EBT-101 overview
EBT-101 is under development for the treatment of HIV-1 infection. The therapeutic candidate constitutes a adeno-associated virus (AAV9) delivering CRISPR/Cas9 guide RNAs directed to HIV-1 LTR U3 upstream promoter region. It is developed based on ViraSuite technology. It is administered through intravenous route.
Excision BioTherapeutics overview
Excision BioTherapeutics (Excision) develops CRISPR (clustered regularly interspaced short palindrome repeats) based therapies to treat infectious diseases. The company is investigating EBT101, a Cas9 (CRISPR associated protein 9) dual RNA (Ribonucleic acid) guided therapeutic for the treatment of HIV (human immunodeficiency virus); EBT103, a Cas9 triplet RNA guided T-antigen therapeutic against JC (John Cunningham) virus induced progressive multifocal leukoencephalopathy. It is also evaluating EBT104, a non viral Cas9 quad RNA guided therapeutic targeting HSV (herpes simplex virus); EBT-107 against HBV (hepatitis B virus); and EBT-201 to prevent and treat COVID-19. The company’s CRISPR gene therapy platform technology is used to develop RNA guided therapies by enabling the probes to examine on- and off-target effects of the disease. Excision BioTherapeutics is headquartered in San Francisco, California, the US.
For a complete picture of EBT-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
